Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Kapan, A; Moser, O; Felsinger, R; Waldhoer, T; Haider, S.
Real-world insights into incretin-based therapy: Associations between changes in taste perception and appetite regulation in individuals with obesity and overweight: A cross-sectional study
DIABETES OBES METAB. 2025;
Doi: 10.1111/dom.16548
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Moser Othmar
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Aims This cross-sectional study examined associations between self-reported taste perception changes and appetite-related outcomes in individuals with obesity treated with glucagon-like peptide-1 receptor agonist (GLP-1 RAS) or dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAS in real-world conditions. Materials and Methods Four hundred and eleven adults on Wegovy (R) (n = 217), Ozempic (R) (n = 148) and Mounjaro (R) (n = 46) completed an online survey assessing sociodemographic, anthropometric and sensory changes and appetite-related outcomes. Multivariable logistic regression was used to assess associations between taste changes and satiety, appetite and craving. Results Participants (69.6% female; median age 39 [interquartile range, IQR 33-47]) had baseline body mass index (BMI) of 35.6 (Wegovy (R)), 34.7 (Ozempic (R)) and 36.2 kg/m(2) (Mounjaro (R)). Adjusted models for baseline BMI, treatment duration, dose, age and sex showed significant reductions in BMI of 17.6% (95% CI: 15.7-19.5) for Wegovy (R), 17.4% (15.0-19.8) for Ozempic (R) and 15.5% (8.8-22.2) for Mounjaro (R). Reduced appetite was reported by 58.4% of participants (Wegovy (R): 54.4%, Ozempic (R): 62.1%, Mounjaro (R): 56.5%) and increased satiety by 63.5% (Wegovy (R): 66.8%, Ozempic (R): 58.8%, Mounjaro (R): 63.1%). Additionally, 21.3% reported increased sweet taste perception and 22.6% reported increased salty taste perception. Independent of the type of therapy, increased sweet taste perception was significantly associated with increased satiety (adjusted odds ratios [AOR] = 2.02; 95% CI: 1.15-4.57), decreased appetite (AOR = 1.67; 95% CI: 1.04-3.25) and decreased craving (AOR = 1.85; 95% CI: 1.05-3.29). Increased salty taste perception was associated with increased satiety (AOR = 2.17; 95% CI: 1.16-5.17; all p < 0.05). Conclusions Self-reported changes in taste perception during GLP-1 or dual GIP/GLP-1 RAS therapy were associated with favourable appetite-related outcomes, suggesting a potential mechanism contributing to treatment response.
- Find related publications in this database (Keywords)
- appetite regulation
- incretin-based therapy
- obesity treatment
- observational study
- weight management